Jennifer Lane, MD


Jennifer Lane, MD
Versus Arthritis Clinical Research Fellow in Orthopaedic Surgery, NDORMS
University of Oxford

Jenny studied undergraduate medicine at Exeter College, University of Oxford, where she was awarded Scholar status. Graduating from clinical medicine in 2010, she undertook basic medical and surgical training in London. In 2014, Jenny graduated with distinction from Masters of Surgical Education degree at Imperial College, London, and returned to Oxford as NIHR Academic Clinical Fellow to undertake combined academic and higher clinical training in Orthopaedic Surgery. She was awarded a Versus Arthritis Clinical Research Fellowship and a Medical Research Council Doctoral Training Fellowship in July 2017, and began DPhil study into the Epidemiology of Common Hand Conditions in December 2017.

Jenny is working with professor Dominic Furniss and professor Dani Prieto Alhambra within NDORMS alongside professor Jane Green in the Nuffield Department of Population Health. She is interested in how routinely collected big data can be recycled to improve our understanding of the role of surgery within medical treatment. She has focused on investigating trends in surgery for common hand conditions, and factors associated with both the need for surgery and with adverse outcomes following surgery. Jenny is also investigating the role of hormonal factors upon the development and progression of musculoskeletal disease in women. Using the Million Women Study, she is exploring reproductive and menopausal factors that may be implicated in developing surgical disease and is interested in investigating the interaction of hormonal treatments with musculoskeletal disease.

Jenny took part in the Barcelona studyathon and is enthusiastic about comparing UK data with other countries, in order to explore differences in surgeon, hospital and healthcare factors that may impact outcomes from surgery. She is now moving forward with a new study within the Women of OHDSI initiative that aims to evaluate the association between the use of hormonal drugs in the treatment of breast cancer with musculoskeletal events, that will call for collaborators in Spring 2020.